Personal Health Solutions from NaturalNews Replace your toxic laundry detergent with natural laundry soap that grows on trees! (NEW source!) This top "underground" natural health newsletter brings you amazing new natural cures each month. Save $100! How to treat and cure over 100 health conditions using little-known health secrets How to halt type-2 diabetes with nutritional therapy - over 50% cure rate proven in studies End cravings with this guide to natural appetite suppressants (Download edition available.) How to blend nutritious meals in minutes with Adams' Superfood smoothie recipes (Delicious!) Breakthrough LED lighting technology prevents global warming, saves 90% on your lighting bill • Browse more health books... • Shop our eco-friendly products... All sales help fund naturalnews operations.

"It is estimated that more than 30 million people worldwide take nonsteroidal anti-inflammatory drugs (NSAIDs) daily for treatment of pain and inflammation," according to background information provided in one of the articles. Adverse effects of some conventional NSAIDs include toxic gastrointestinal (GI) effects, as well as adverse renal (kidney) effects. "Overall, an estimated 2.5 million individuals in the United States annually experience adverse renal effects caused by use of NSAIDs," the authors write. "With decreased risk of adverse GI effects, a class of drugs that selectively inhibits COX-2 enzyme was introduced for analgesia (pain relief) and the treatment of arthritis." According to the authors, the adverse renal effects of selective COX-2 inhibition are unclear. Evidence is accumulating on the potential class effect of COX-2 inhibitors on cardiovascular risk. Two COX-2 inhibitors have already been withdrawn from the market: rofecoxib (marketed as Vioxx) and valdecoxib (marketed as Bextra).

Jingjing Zhang, M.D., Ph.D., from Brigham and Women's Hospital and Harvard Medical School, Boston, and colleagues evaluated the adverse risks of renal events and arrhythmia (disturbance of the normal heart rhythm) events in patients prescribed COX-2 inhibitors from a systematic review of the medical literature to determine if these negative side-effects involve every drug in this class.

"In this comprehensive meta-analysis of 114 randomized trials of COX-2 inhibitors comprised of 116,094 participants, rofecoxib uniquely increased risks of renal events (peripheral edema, renal dysfunction, hypertension) and arrhythmia events, with apparent adverse effects by the end of year 2000 and 2004, respectively," the researchers write. "However, the results did not show adverse effects of other COX-2 inhibitors on renal events and arrhythmia, indicating no overall evidence for a COX-2 inhibitor class effect."

In conclusion, the authors write: "Notably for policy and clinical decision making, our results also suggest that a time-cumulative meta-analytic approach for examining available trial safety data would have helped clarify apparently adverse effects several years earlier than the current report. The knowledge of all potential adverse effects is important and indeed time-sensitive, for physicians and patients both need complete information about risks and benefits to properly use COX-2 inhibitors and other clinical treatments." They continue, "future drug safety monitoring of emerging clinical treatments may benefit from continuous cumulative meta-analytic aggregation of safety data for all drug-approval applications and experimental agents." (JAMA. 2006; 296:doi:10.1001/jama.296.13.jrv60015. Available pre-embargo to the media at www.jamamedia.org)

Editor's Note: Corresponding author Mr. Ding was supported by a grant from the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) and by an institutional training grant from the National Cancer Institute, National Institutes of Health. Dr. Song was supported by grants from the NIDDK, National Institutes of Health. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

In a related study, Patricia McGettigan, M.B.B.S., B.Pharm., F.R.A.C.P., Ph.D., and David Henry, M.B., Ch.B., F.R.C.P., from The University of Newcastle, New South Wales, Australia, conducted a meta-analysis of the observational studies in the medical literature to compare the risks of serious cardiovascular events (predominantly, myocardial infarction [heart attack]) with individual NSAIDs and cyclooxygenase 2 inhibitors (COX-2).

In background information, the authors write that interest in the cardiovascular effects of the relatively selective inhibitors of COX-2 has been intense. Although rofecoxib was withdrawn from world markets, celecoxib (marketed as Celebrex) "continues to be widely used, despite meta-analyses of randomized controlled trials showing an increased risk of myocardial infarction." The authors add, "attention has turned to the cardiovascular safety of the older non-selective non-steroidal anti-inflammatory drugs (NSAIDs). These agents are used extensively and some are available in many countries without prescription."

The authors based their analysis on 17 case-control analyses that included 86,193 cases with cardiovascular events and over 500,000 controls, and six cohort analyses that included 75,520 users of selective COX-2 inhibitors, 375,619 users of nonselective NSAIDs, and nearly 600,000 unexposed participants.

"A dose-related risk was evident with rofecoxib (relative risk 1.33 with 25 milligrams or less per day and 2.19 with more than 25 mg/day)," the authors report. "The risk was elevated during the first month of treatment. Celecoxib was not associated with an elevated risk of vascular occlusion. Among older non-selective drugs, diclofenac had the highest risk with a summary relative risk of 1.40. The other drugs had summary relative risks close to one: naproxen, 0.97; piroxicam, 1.06; and ibuprofen 1.07." The authors state that this review "contradicts claims of a 'protective' effect of naproxen and raises serious questions about the safety of diclofenac …"

"In conclusion, controlled data from observational and randomized studies confirm a dose-related risk of cardiovascular events with selective COX-2 inhibitors. The observational data indicate that the risk increases early in treatment. An older NSAID, diclofenac, seems to share this risk and, unlike celecoxib, it appears to be harmful at commonly used doses. We believe there are grounds for reviewing its regulatory status." (JAMA. 2006; 296: doi:10.1001/JAMA.296.13.jrv60011. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: Funding for this review was provided through project grants from the National Health and Medical Research Council of Australia and the National Heart Foundation Australia. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Contact: Todd Datz 617-432-3952 JAMA and Archives Journals

Related Articles

Additional Resources: COX-2 inhibitors NSAIDs COX-2 inhibitor	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/020918.html Reprinting this article: Non-commercial OK, cite NaturalNews.com with clickable link. <a href = "http://www.NaturalNews.com/020918.html">Studies provide new evidence on risks associated with Cox-2 inhibitors and NSAIDs (press release)</a>
Receive our Natural Health Newsletter for FREE Subscribe now (it's free!) to win. We randomly choose a subscriber each month to send $100 in eco-home products or a RealGoods.com gift certificate (our choice). Plus, you'll receive FREE news, articles and action alerts from NaturalNews.com editors and join over 800,000 monthly readers who report extraordinary health improvements after becoming a subscriber! Receive breaking news alerts on natural health solutions, renewable energy, the environment, global warming and more. Receive a free instant download of our $29 Secret Sources guide that reveals top sources for little-known health and diet solutions.	Your Email Address: Free Subscription Code: Enter the numbers you see: 100% free of charge. Unsubscribe anytime. Absolutely no spam. We respect your email privacy.
Recommended Special Report: Seven Words that can Change the World by Joseph R. Simonetta Read this special report now... "Seven Words That Can Change the World reveals the astonishing, simple truths that have the power to forever transform our world for the better while freeing our minds from the enslavement of limiting beliefs. This is not a text for the simple-minded; it is a guiding philosophy for the mindful, intelligent few who are wise enough to seek out -- and recognize -- the higher simplicities of truly purposeful living." - Mike Adams, the Health Ranger, editor of NaturalNews.com	More on NaturalNews.com: • Streaming Health Ranger Videos • CounterThink Cartoons • FREE Special Reports • Podcasts